| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/23/2003 | WO2003006607A2 Inhibition of apoptosis process and improvement of cell performance |
| 01/23/2003 | WO2003006506A2 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006059A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006056A2 End-locked five-helix protein |
| 01/23/2003 | WO2003006055A2 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 01/23/2003 | WO2003006048A1 Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006033A2 Herbal formulation |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003005957A2 Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith |
| 01/23/2003 | WO2003005955A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2003005952A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | WO2003005888A2 Lipophilin complexes for use in cancer diagnosis and therapy |
| 01/23/2003 | WO2003005880A2 Replikin peptides and uses thereof |
| 01/23/2003 | WO2002086058A3 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002067984A9 Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection |
| 01/23/2003 | WO2002066509A3 Treatment involving dkk-1 or antagonists thereof |
| 01/23/2003 | WO2002060476A3 Tumor vaccine |
| 01/23/2003 | WO2002048388A9 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 01/23/2003 | WO2002046364A9 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/23/2003 | WO2002036790A3 Influenza virus vector for infection of dendritic cells |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002034778A3 Baseb209 polypeptides and polynucleotides from haemophilus influenzae |
| 01/23/2003 | WO2002034768A3 Polypeptides and polynucleodides from haemophilus influenzae and their use |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002030457A3 Microbes having an attenuating mutation comprising a transcription terminator |
| 01/23/2003 | WO2002029059A3 Nogo receptor homologs |
| 01/23/2003 | WO2002022659A3 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002020569A3 Mammalian genes; related reagents and methods |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002016598A3 Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers |
| 01/23/2003 | WO2002012272A3 Therapeutic anti-melanoma compounds |
| 01/23/2003 | WO2002011761A3 Vaccine against rsv |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008293A3 Multivalent target binding protein |
| 01/23/2003 | WO2002008262A3 Bstp-5 proteins and related reagents and methods of use thereof |
| 01/23/2003 | WO2001097843A3 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 01/23/2003 | WO2001089548A3 Pharmaceutical use of fibulin-1 |
| 01/23/2003 | WO2001089364A3 Hcv variants |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018181 Antiinflammatory agents; culturing; isolation of fusion protein |
| 01/23/2003 | US20030018178 Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| 01/23/2003 | US20030018165 Uses of suppressive macrophage activation factors |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030018004 Vector |
| 01/23/2003 | US20030017985 Molecules that influence pathogen resistance |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017547 Nucleotide sequences coding polypeptide for use in the treatment of cancer |
| 01/23/2003 | US20030017509 Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus |
| 01/23/2003 | US20030017495 Enterococcus faecalis polynucleotides and polypeptides |
| 01/23/2003 | US20030017494 Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| 01/23/2003 | US20030017491 Chromogenic in situ hybridization methods, kits, and compositions |
| 01/23/2003 | US20030017478 Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof |
| 01/23/2003 | US20030017468 Nucleotide sequences which code lung preferential gene for use in the treatment and diagnosis of lung cancer |
| 01/23/2003 | US20030017466 Diagnosi and treatment of cancer; obtain tissue sample, monitor gene expression in sample, monitor methylation in sample, compare to control, evaluate for cancer |
| 01/23/2003 | US20030017456 Diagnosis and treatment and related preparations |
| 01/23/2003 | US20030017450 Detection of viral nucleotide sequences in sample; obtain sample, denature, incubate with pimers, hybridize, amplify, expose to probe, detect signal presence indicates viral nucleotide sequences |
| 01/23/2003 | US20030017448 Preventing uterine infection of fetuses; obtain swine, administer antibodies, monitor swine births for infected fetus, no infection indicates preventive antibody |
| 01/23/2003 | US20030017174 Containing herpes simplex virus VP22 polypeptides capable of eliciting a cellular immune response |
| 01/23/2003 | US20030017172 Feline polynucleotide vaccine formula |
| 01/23/2003 | US20030017171 Also contains an antigen of swine influenza virus, porcine reproductive and respiratory syndrome virus, or porcine circovirus; an acrylic acid polymer, metabolizable oil and an oxyethylene-oxypropylene block polymer as adjuvant |
| 01/23/2003 | US20030017168 Antigen delivery |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017165 Chemically programmable immunity |
| 01/23/2003 | US20030017162 Preventing and treating Gram-negative sepsis. |
| 01/23/2003 | US20030017161 Polypeptides that are capable of modulating apoptosis; also Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 |
| 01/23/2003 | US20030017159 Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017156 Immunogenic polypeptide |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017152 Administering a substance that specifically depletes alpha beta -, and gamma delta -TCR+ T cells and/or CD8+ T cells, followed by transplantation with a donor cell preparation containing hematopoietic stem cells from a matched donor |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017147 Novel alpha-2-antiplasmin- binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient |
| 01/23/2003 | US20030017143 Reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28- T cells |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017134 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453474A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453161A1 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | CA2453136A1 Replikin peptides and uses thereof |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2452382A1 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2450898A1 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | CA2449243A1 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 01/23/2003 | CA2447585A1 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277837A2 Epididymis-specific DNA sequences and their use |
| 01/22/2003 | EP1277764A2 Allergenic proteins and peptides from dog dander and uses therefor |